SUPPLEMENTARY TABLE 1. ICD-10 diagnosis codes used to define cohort of patients with acute respiratory infection in IQVIA.

ICD 10 Code	ICD 10 Code Description
J00.*	Acute nasopharyngitis (common cold)
J01.*	Acute sinusitis
J02.*	Acute pharyngitis
J03.*	Acute tonsillitis
J04.*	Acute laryngitis and tracheitis
J05.*	Acute obstructive laryngitis and epiglottis
J06.*	Acute upper respiratory infection of multiple and unspecified sites
J09.*	Influenza due to certain identified influenza viruses
J10.*	Influenza due to other identified influenza virus
J11.*	Influenza due to unidentified influenza virus
J12.*	Viral pneumonia, not elsewhere classified
J13.*	Streptococcus pneumoniae Pneumonia
J14.*	Hemophilus influenzae Pneumonia
J15.*	Bacterial pneumonia, not elsewhere classified
J16.*	Pneumonia due to other specified infectious organism, not elsewhere classified
J17.*	Pneumonia in diseases classified elsewhere
J18.*	Pneumonia, unspecified organism
J20.*	Acute bronchitis
J21.*	Acute bronchiolitis
J22	Unspecified acute lower respiratory tract infection
J40	Bronchitis, not specified as acute or chronic
J80	Acute respiratory distress syndrome
J98.8	Other specified respiratory disorders
A22.1	Pulmonary anthrax
A37.91	Whooping cough, unspecified species, pneumonia
A37.01	Whooping cough: Bordetella pertussis, pneumonia
A37.11	Whooping cough: B. parapertussis, pneumonia
A37.81	Whooping cough: other Bordetella, pneumonia
A48.1	Legionnaire's Disease
B25.0	Cytomegaloviral pneumonitis
B44.0	Invasive pulmonary aspergillosis
B97.4	Respiratory syncytial virus as the cause of diseases classified elsewhere
O98.5	Other viral diseases complicating pregnancy, childbirth and the puerperium
Z20.828	Contact with and (suspected) exposure to other viral communicable diseases
Z03.818	Encounter for observation for suspected exposure to other biological agents ruled out
Z11.59	Encounter for screening for other viral diseases

R09.02	Hypoxemia
R06.03	Acute respiratory distress
R50.9 and (R06.02 or R06.00 or R05)	R50.9 Fever, unspecified AND (either R06.02 Shortness of breath OR R06.00 Dyspnea, unspecified OR R05 Cough)
J85.1	Abscess of lung with pneumonia

SUPPLEMENTARY TABLE 2. Criteria and codes used to identify healthcare encounters possibly related to SARS-CoV-2 infection in CDC-licensed HealthVerity data.*

Category	Condition / Description	Codes
Diagnoses (ICD-10-CM Codes)	Influenza-Like-Illness	B97.89, J06.9, J12.89, J12.9, J18.1, J18.8, J18.9
		J09.*, J10.*, J11.*
	Upper respiratory	J00.*, J01.*, J02.*, J03.*, J04.*, J05.*, J06.*
	Influenza	J09.*, J10.*, J11.*
	Pneumonia	J12.*, J13.*, J14.*, J15.*, J16.*, J17.*, J18.*
	COVID-19	B97.29, B34.2, U07.1, U07.2
	History of COVID-19	Z86.16
	Cough	R05.*
	Shortness of Breath	R06.02
	Fever	R50.9
	Acute Respiratory Distress Syndrome	J80.*
	Diarrhea	R19.7
	Fatigue	R53.8
	Sputum/Hemoptysis	R09.3, R04.2
	Hypoxia	R09.2
Laboratory tests or procedures (CPT Code Groups)	COVID-19 NAAT	87635, U0001, U0002, U0003, U0004, 87426, 87636, 87637, 87811
	COVID-19 Antibody	86328, 86769, 86413
	Bevacizumab	J90.35
	Tocilizumab	J32.62
	Interferon beta-1a	J18.26, Q30.27, Q30.28
	Eculizumab	J13.00
	Siltuximab	J28.60, C94.55
	Casirivumab/Imdevimab	Q02.43, M02.43
	Bamlanivimab	M02.39, Q02.39
	Bamlanivimab/Etesivimab	Q02.45, M02.45
Treatments[†]	Oseltamivir	
	Chloroquine	
	Hydroxychloroquine	
	Lopinavir/ritonavir	
	Tocilizumab	
	Sarilumab	
	Baricitinib	
	Baloxavir marboxil	
	Emtricitabine/Tenofovir disoproxil fumarate	
	Darunavir and Cobicistat	
	Interferon beta-1a	

	Fingolimod
	Eculizumab
	Aliskiren
	Anakinra
	Angiotensin II
	Emapalumab-lzsg
	Lucinactant (Surfaxin)
	Ruxolitinib
	Siltuximab
	Caplacizumab
	Dupilumab
	Casirivimab
	Idemivab
	Sotrovimab
	Bamlanivimab
	Etesevimab

*Patients were eligible for inclusion in the CDC-licensed HealthVerity data if they had a diagnosis, procedure, treatment, or laboratory test of interest in medical claims, pharmacy claims, hospital charge master, or laboratory data sources.

[†] The list of eligible treatments was developed by HealthVerity in conjunction with clinical experts tracking the pandemic in order to identify known or suspected COVID-19 cases. Known, suspected, and potentially experimental medications used to treat SARS-CoV-2 infection were included, even if those treatments ultimately proved to be ineffective. All available National Drug Codes were used to identify the listed medications in patient pharmacy claims.